Brief: Cutia Therapeutics Says Cu-40102 Obtains Marketing Approval By Hong Kong Department Of Health
01/08/2025 11:30
Aug 1 (Reuters) - Cutia Therapeutics 2487.HK: CU-40102 OBTAINS MARKETING APPROVAL BY HONG KONG DEPARTMENT OF HEALTH Further company coverage: 2487.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China